Responses
Clinical/translational cancer immunotherapy
Original research
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
Compose a Response to This Article
Other responses
No responses have been published for this article.